Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention

  • Juan Carlos Castillo Department of Human Assisted Reproduction, Instituto Bernabeu, Alicante, Spain
  • Thor Haahr Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; The Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark
  • María Martínez-Moya Department of Human Assisted Reproduction, Instituto Bernabeu, Alicante, Spain
  • Peter Humaidan Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; The Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark
Keywords: Cancer, GnRH trigger, hCG, IVF, oocyte donation, ovulation trigger

Abstract

In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention. The GnRHa trigger concept has sparked the development of novel protocols, enriching the assisted reproductive technology (ART) armamentarium for the benefit of present and future patients. Thus, GnRHa trigger already has a pivotal role, not only for the standard in vitro fertilisation (IVF) patient, but also for patient groups like oocyte donors, cancer patients, patients with poor ovarian reserve, and patients with immature oocyte syndrome and empty follicle syndrome. Herein, we discuss the importance of the GnRHa-elicited midcycle FSH surge and the potential improvement in oocyte yield and embryo competence.

Downloads

Download data is not yet available.
Published
2020-03-25
How to Cite
Castillo J. C., Haahr T., Martínez-Moya M., & Humaidan P. (2020). Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention. Upsala Journal of Medical Sciences, 125(2), 138-143. https://doi.org/10.1080/03009734.2020.1737599